Cambrian Genomics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cambrian Genomics Inc. - overview
Established
2011
Location
San Francisco, CA, US
Primary Industry
Healthcare IT
About
Cambrian Genomics Inc. is a biotechnology company focusing on advanced genetic sequencing technologies, aimed at enhancing genomic understanding and facilitating personalized medical therapies for diverse clients across the globe. Founded in 2011 and headquartered in San Francisco, US, Cambrian Genomics Inc. specializes in genomics and has undergone strategic pivots to hone its focus on genetic sequencing technologies.
The company was founded by Austen Heinz, who has a background in entrepreneurship. Cambrian Genomics raised a total of USD 11. 23 mn through its Series A funding round on December 19, 2014, led by Velo Partners and supported by Draper Associates. The company has completed three funding deals and currently holds a valuation of USD 68.
244 mn. Cambrian Genomics specializes in providing advanced genetic sequencing technologies that enhance genomic research. Their proprietary platform utilizes sequencing by synthesis techniques to determine the arrangement of nucleotide bases in DNA, essential for identifying genetic variations linked to diseases. The company caters to a varied clientele including academic institutions and biotechnology firms, primarily in North America, Europe, and Asia, focusing on innovative genomic solutions.
Cambrian Genomics generates revenue through B2B transactions, offering genomic sequencing services or access to their proprietary platform. They typically employ a revenue model that includes subscription pricing for ongoing services and one-time fees for specific projects, providing comprehensive genomic insights to their clients in the biotechnology and healthcare sectors. Cambrian Genomics plans to utilize the recent Series A funding of USD 11. 23 mn to further develop their sequencing technologies and expand their service offerings.
They are looking to target new markets in Asia and Europe by 2025, aiming to establish partnerships with more healthcare providers and research institutions. The funding will support the launch of upcoming products designed to enhance the accessibility and efficiency of their genomic sequencing capabilities.
Current Investors
Felicis Ventures, Alchemist Accelerator, StartCaps Ventures
Primary Industry
Healthcare IT
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT
Website
www.cambriangenomics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Cambrian Genomics Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.